The epigenetic impact of suberohydroxamic acid and 5-Aza-2'-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F22%3A73614993" target="_blank" >RIV/61989592:15110/22:73614993 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/22:A2302JLI RIV/00216208:11110/22:10447687 RIV/00098892:_____/22:10157748

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471560/" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471560/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/mmr.2022.12837" target="_blank" >10.3892/mmr.2022.12837</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The epigenetic impact of suberohydroxamic acid and 5-Aza-2'-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression

Popis výsledku v původním jazyce

Gene inactivation of the cyclin-dependent kinase inhibitors p16INK4a, p15INK4b and p21WAF is frequently mediated by promoter gene methylation, whereas histone deacetylases (HDACs) control gene expression through their ability to deacetylate proteins. The effect of suberohydroxamic acid (SBHA) and 5-Aza-2&apos;-deoxycytidine (Decitabine) (DAC) treatments on the transcription of CDKN2A, CDKN2B and CDKN1A genes, and their effects on molecular biological behavior were examined in two myeloma cell lines, RPMI8226 and U266, which differ in p53-functionality and IL-6 expression. In both tested myeloma cell lines, a non-methylated state of the CDKN2B gene promoter region was detected with normal gene expression, and the same level of p15INK4b protein was detected by immunocytochemical staining. Furthermore, in myeloma cells treated with SBHA and DAC alone, the expression of both p15INK4b and p21WAF was significantly upregulated in RPMI8226 cells (p53-functional, without IL-6 expression), whereas in the U266 cell line (p53 deleted, expressing IL-6) only p21WAF expression was significantly increased. Moreover, the analysis revealed that treatment with DAC induced DNMT3B enhancement in U266 cells. In conclusion, in myeloma cells with IL-6 expression, significantly increased DNMT3B expression indicated the tumorigenic consequences of 5-Aza-2&apos;deoxycytidine treatment, which requires careful use in diseases involving epigenetic dysregulation, such as multiple myeloma (MM). © 2022 Spandidos Publications. All rights reserved.

Název v anglickém jazyce

The epigenetic impact of suberohydroxamic acid and 5-Aza-2'-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression

Popis výsledku anglicky

Gene inactivation of the cyclin-dependent kinase inhibitors p16INK4a, p15INK4b and p21WAF is frequently mediated by promoter gene methylation, whereas histone deacetylases (HDACs) control gene expression through their ability to deacetylate proteins. The effect of suberohydroxamic acid (SBHA) and 5-Aza-2&apos;-deoxycytidine (Decitabine) (DAC) treatments on the transcription of CDKN2A, CDKN2B and CDKN1A genes, and their effects on molecular biological behavior were examined in two myeloma cell lines, RPMI8226 and U266, which differ in p53-functionality and IL-6 expression. In both tested myeloma cell lines, a non-methylated state of the CDKN2B gene promoter region was detected with normal gene expression, and the same level of p15INK4b protein was detected by immunocytochemical staining. Furthermore, in myeloma cells treated with SBHA and DAC alone, the expression of both p15INK4b and p21WAF was significantly upregulated in RPMI8226 cells (p53-functional, without IL-6 expression), whereas in the U266 cell line (p53 deleted, expressing IL-6) only p21WAF expression was significantly increased. Moreover, the analysis revealed that treatment with DAC induced DNMT3B enhancement in U266 cells. In conclusion, in myeloma cells with IL-6 expression, significantly increased DNMT3B expression indicated the tumorigenic consequences of 5-Aza-2&apos;deoxycytidine treatment, which requires careful use in diseases involving epigenetic dysregulation, such as multiple myeloma (MM). © 2022 Spandidos Publications. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30401 - Health-related biotechnology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Medicine Reports

ISSN

1791-2997

e-ISSN

1791-3004

Svazek periodika

26

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

14

Strana od-do

"article number 321"

Kód UT WoS článku

000854740500001

EID výsledku v databázi Scopus

2-s2.0-85136952107